REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals (REGN) Business News

Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
2:25 PM | Thursday | Jun 4, 2026 Zacks Investment Research

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

News Thumbnail
10:00 AM | Thursday | Jun 4, 2026 PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

News Thumbnail
7:00 AM | Thursday | Jun 4, 2026 GlobeNewsWire

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

News Thumbnail
10:00 AM | Thursday | Jun 4, 2026 PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

News Thumbnail
7:00 AM | Thursday | Jun 4, 2026 GlobeNewsWire

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

News Thumbnail
4:32 PM | Tuesday | Jun 2, 2026 GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

News Thumbnail
11:35 AM | Monday | Jun 1, 2026 Zacks Investment Research

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

News Thumbnail
11:35 AM | Monday | Jun 1, 2026 Zacks Investment Research

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

News Thumbnail
12:31 PM | Friday | May 29, 2026 Zacks Investment Research

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

News Thumbnail
11:04 AM | Thursday | May 28, 2026 24/7 Wall Street

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

News Thumbnail
10:00 AM | Thursday | May 28, 2026 PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

News Thumbnail
4:53 PM | Tuesday | May 26, 2026 GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

News Thumbnail
11:31 AM | Monday | May 25, 2026 Newsfile Corp

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

News Thumbnail

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

Zacks Investment Research

2:25 PM | Thursday | Jun 4, 2026

news photo
Loading...

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

Read full article redirect
2:25 PM | Thursday | Jun 4, 2026

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

Zacks Investment Research

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Jun 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

PRNewsWire

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jun 4, 2026

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

GlobeNewsWire

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Jun 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

PRNewsWire

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jun 4, 2026

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

GlobeNewsWire

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026.

Read full article arrow
News Thumbnail
4:32 PM | Tuesday | Jun 2, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

GlobeNewsWire

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Read full article arrow
News Thumbnail
11:35 AM | Monday | Jun 1, 2026

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

Zacks Investment Research

REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.

Read full article arrow
News Thumbnail
11:35 AM | Monday | Jun 1, 2026

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

Zacks Investment Research

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Read full article arrow
News Thumbnail
12:31 PM | Friday | May 29, 2026

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Read full article arrow
News Thumbnail
11:04 AM | Thursday | May 28, 2026

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

24/7 Wall Street

If you're looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech innovators.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | May 28, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

PRNewsWire

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Read full article arrow
News Thumbnail
4:53 PM | Tuesday | May 26, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

GlobeNewsWire

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Read full article arrow
News Thumbnail
11:31 AM | Monday | May 25, 2026

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

Newsfile Corp

Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Read full article arrow
News Thumbnail